Biohaven Pharmaceutical Holding Company Ltd , a clinical stage biopharmaceutical company targeting neurological diseases, including rare disorders, has closed the second tranche of its $80 million private placement. Venrock was the lead investor.
Biohaven Pharmaceutical Holding Company Ltd , a clinical stage biopharmaceutical company targeting neurological diseases, including rare disorders, has closed the second tranche of its $80 million private placement. Venrock was the lead investor.